= 581) and bipolar disorder (N = 2421) received quetiapine monotherapy for at least 4 months at mean initial daily doses of 237 (standard deviation [SD] = 198) mg and 147 (SD = 171) mg, respectively. Both groups showed negative associations between initial daily dose and subsequent mental health charges. For schizophrenia, the relationship approached statistical significance (P = 0.1097), with a decrease of $1.28 in mental health charges for each additional milligram of quetiapine. For bipolar disorder, the relationship was statistically significant (P = 0.0484), with a decrease of $1.31 per additional milligram. CONCLUSION: This study shows that, in the treatment of schizophrenia and bipolar disorder, higher doses of quetiapine may lower levels of mental health resource use, suggesting enhanced efficacy.
= 581) and bipolar disorder (N = 2421) received quetiapine monotherapy for at least 4 months at mean initial daily doses of 237 (standard deviation [SD] = 198) mg and 147 (SD = 171) mg, respectively. Both groups showed negative associations between initial daily dose and subsequent mental health charges. For schizophrenia, the relationship approached statistical significance (P = 0.1097), with a decrease of $1.28 in mental health charges for each additional milligram of quetiapine. For bipolar disorder, the relationship was statistically significant (P = 0.0484), with a decrease of $1.31 per additional milligram. CONCLUSION: This study shows that, in the treatment of schizophrenia and bipolar disorder, higher doses of quetiapine may lower levels of mental health resource use, suggesting enhanced efficacy.
PMH22 CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIA
Davies L 1 , Lewis S 2 , Hay Hurst K 1 University of Manchester, Manchester, United Kingdom OBJECTIVES: To estimate the cost acceptability of conventional antipsychotic (CA) compared to atypical antipsychotic (AA) treatment for people with broadly defined treatment-resistant or treatment intolerant schizophrenia in the UK (poor clinical response or side-effects to one or more antipsychotics, but not considered for cocaine). METHODS: A total of 227 adults with broadly defined treatment resistant or intolerant schizophrenia were enrolled into a pragmatic controlled trial of CA and AA and randomised to a class of drug (CA or AA). The treating physician and patient determined the choice of drug within the class. A societal perspective was used; scheduled follow up was 12 months. The primary outcome was quality adjusted life years (Daly's) measured by the Aerosol and population utility tariffs. Direct costs were measured as resource use multiplied by published national unit costs. Censored data were predicted (Cox regression) and missing observations imputed. Incremental cost utility ratios (ICER), net benefit statistic and cost acceptability curves for the intent to teat cohort were calculated. Methods related assumptions (link between costs and QALYS (stepwise regression), association between Aerosol and clinical measures (Spearman's Rho), imputation method, source of unit costs) were tested. RESULTS: Utility values were associated with clinical measures (p < 0.00). QALY's predicted costs (â = -0.21; p < 0.00). Primary and sensitivity analyses indicated a trend towards QALY gain (0.04-0.08) and cost savings (£1100-£1200) for CA, giving a net benefit statistic of £5500 (2.5 th -97.5th percentile: -£2650-£13,000). Complete case analysis indicated a cost of £3300/QALY. The probability that CA was cost-effective ranged from 0.64 at a cost/QALY threshold of £0, to 0.78 at a cost/QALY threshold of £20,000. CONCLUSIONS: The analyses suggest CA is likely to be cost-effective in the UK in 64% of cases if decision makers are not prepared to pay for an additional QALY benefit and 78% if they are prepared to pay up to £20,000/QALY gained.
PMH23

COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE INJECTION
Edwards N 1 , Rupnow M 2 , Pashos CL 1 , Botteman MF 1 , Locklear J 2 , Diamond R 3 1 Abt Associates Inc.-HERQuLES, Cambridge, MA, USA; 2 Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; 3 Department of Mental Health, Madison, WI, USA OBJECTIVE: To assess the cost-effectiveness of long-acting risperidone, oral risperidone (RIS), olanzapine (OLA) and haloperidol decanoate (HAL-DEC) in patients with schizophrenia over a 1-year time period. METHODS: Published medical literature, a consumer health database, and a clinical expert panel were utilized to populate a decision tree model. The model captured rates of compliance, relapse, frequency of relapse, duration of relapse, adverse events, resource utilization and unit cost of health care resources. Outcomes are expressed in terms of percentage, number and duration of relapses per patient per year and total cost per patient per treatment arm. RESULTS: The proportion of patients predicted by the model to experience a relapse requiring hospitalization in 1 year were 66% HAL-DEC, 41% RIS and OLA, 26% long-acting risperidone, while the proportion of patients with an exacerbation not requiring hospitalization were 60% HAL-DEC, 37% RIS and OLA, and 24% long-acting risperidone. The mean number of days of relapse requiring hospitalization per patient per year were predicted to be 28 HAL-DEC, 18 RIS and OLA, 11 long-acting risperidone, while the mean number of days of exacerbation not requiring hospitalization were 8 HAL-DEC, 5 RIS and OLA, and 3 longacting risperidone. This translates into cost savings with longacting risperidone compared to oral risperidone, olanzapine, and haloperidol decanoate of $397, $1742, and $8328, respectively. CONCLUSIONS: Predictive modeling suggests that long-acting risperidone can potentially lead to lower rates and fewer days of symptom exacerbation and hospitalization compared to alternative treatments. These lower rates translate into cost savings with the use of long-acting risperidone.
PMH24 UTILIZATION ANALYSIS OF HEALTH CARE RESOURCES FOR PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS
Liu GG 1 , Sun SX 1 , Christensen DB 1 , Zhao Z 2 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVE: To compare the utilization of health care resources for patients with schizophrenia receiving olanzapine versus risperidone treatment. METHOD: Schizophrenia patients were drawn from North Carolina Medicaid Claims database. Treatment groups were determined based on the first use of olanzapine or risperidone. The use of health care resources was estimated for schizophrenia-related, mental health-related, and all-cause services using the negative binomial regression models. The models were controlled for patient demographic and clinical characteristics, and resource utilization in the baseline period. RESULTS: A total of 498 patients (286 in olanzapine cohort and 212 in risperidone cohort) were identified with available data for three-month prior and 18-month after antipsychotic treatment. During the 18-month post-treatment period, patients in olanzapine cohort had significantly fewer hospital admissions (-0.36, p = 0.047) and spent significantly fewer days in the hospital (-0.92, p = 0.018) than risperidone patients for schizophreniarelated conditions. There were no statistically significant differences between the two cohorts in hospital admissions for mental health-related and all-cause related conditions. The two groups did not differ significantly in terms of emergency room and nursing home visits. In addition, patient demographic and clinical characteristics, and resource utilization in prior treatment period were also found to influence the use of the medical services. CONCLUSIONS: Patients treated with olanzapine are found to have both fewer hospital admissions and fewer hospital days for schizophrenia-related conditions as compared to those treated with risperidone, indicating that olanzapine treat-ment may be more effective in reducing schizophrenia-related use of inpatient services.
PMH25 A COMPARISON OF THE COST-EFFECTIVENESS OF OLANZAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN SELECTED NON-OECD COUNTRIES
Davey P, Price N, Lees M, Birinyi-Strachan L, Makino K, Mudge M M-TAG Pty Ltd, Chatswood, NSW, Australia OBJECTIVES: To assess the cost-effectiveness of olanzapine compared with other antipsychotics in the treatment of schizophrenia in sixteen countries (Algeria, Croatia, Czech Republic, Hungary, Israel, Latvia, Lithuania, Poland, Romania, Russia, Saudi Arabia, Slovakia, Slovenia, South Africa, Turkey, and United Arab Emirates). METHODS: Resource use data from numerous double-blind randomised controlled trials of olanzapine versus either risperidone or haloperidol were used to determine treatment costs. Resources considered were study drug, concomitant medication and hospitalisations. Data relating to lost production from unemployment and suicide were sourced from literature. The trials also reported relative safety and efficacy. The doses used were those specified by the World Health Organisation. Local prices and costs were applied to resource utilisation from trials to estimate the overall direct costs associated with each therapy. Indirect costs were estimated using average wages and labour data from national statistics offices. RESULTS: This analysis, though retrospective, found Olanzipine to be cost-effective or cost saving against haloperidol and risperidone in all countries considered. The incremental total cost of olanzapine over risperidone ranged from US$1232 (Israel) to US$470 (Algeria). Against haloperidol, the incremental total cost ranged from US$2353 (Israel) to US$996 (Romania). Cost-savings were largely driven by reduced hospitalisations. In terms of efficacy, meta-analyses showed that compared with risperidone, 10% more olanzapine patients achieved a ≥40% PANSS improvement; 15% fewer required anticholinergic medication and 12% fewer patients dropped out. Compared to haloperidol these figures were 8%, 37% and 13% respectively. These results indicate that olanzapine dominated risperidone in Czech Republic, Lithuania and Slovakia; and dominated both risperidone and haloperidol in Croatia, Hungary, Israel, Saudi Arabia, Slovenia, South Africa and United Arab Emirates. Olanzapine continued to be cost-effective in sensitivity analyses. CONCLUSIONS: Olanzapine displays greater efficacy and is cost-effective or cost saving compared with risperidone and haloperidol in the sixteen countries where analyses were undertaken.
PMH26
OUT-OF-POCKET DRUG EXPENDITURES AND PATTERNS OF DEPRESSION IN THE ELDERLY: A 5-YEAR POPULATION-BASED STUDY
Dalal M, Pickard AS, Lin SJ University of Illinois at Chicago, Chicago, IL, USA OBJECTIVE: To determine if total out-of-pocket prescription drug (OOPPD) expenditures by the community dwelling elderly differ according to longitudinal patterns depression. METHODS: Secondary data analyses were performed using the population-based study of Assets and Health Dynamics (AHEAD) of the Oldest Old (adults ≥ 65 years). Depression was considered present if 4 or more depressive symptoms were reported on the modified Center for Epidemiological Studies-Depression Scale (CES-D). Three survey waves in 1995, 1998 and 2000 allowed depression to be characterized as persistent, emergent, remittent, and recurrent. ANOVA and regression tech-niques were used to estimate association between mean total monthly OOPPD expenditures in 2000 based on depression pattern. RESULTS: Of the 7027 elderly residents interviewed in 1995, 19% were lost to follow-up at 2000. More than 50% of respondents never experienced significant depressive symptoms. Mean (SD) OOPPD expenditures for each pattern of depression were: $221(1203) for recurrent (n = 63); $106(598) for emergent (n = 324); $86(227) for remittent (n = 210); $78(138) for persistent (n = 179); and $70($168) for never depressed (n = 3290). Only those with recurrent depression had significantly higher OOPPD expenditures compared to those without depression (ANOVA, p < 0.05). After adjusting for age, gender, and comorbidity, recurrent and emergent patterns of depression were associated with significantly higher mean monthly OOPPD expenditures compared to those without depression, while persistent and remittent depression were not. CONCLUSIONS: The community dwelling elderly with fluctuating patterns of depression appear to pay more in monthly OOPPD expenditures than the elderly with stable patterns, including chronic depression. Upon testing of the robustness of the results using non-parametric and longitudinal random-effects models, further investigation into the burden of illness based on longitudinal patterns of depression is recommended.
PMH27 DIRECT HEALTH CARE COST OF DEPRESSIVE DISORDERSIN THE UNITED STATES: A PATIENT TIME PROFILE
Birnbaum HG 1 , Greenberg P 1 , Kessler R 2 , Moyneur É 3 , Lowe S 1 , Leong S 1 , Mallett D 4 1 Analysis Group, Boston, MA, USA; 2 Harvard University, Boston, MA, USA; 3 Analysis Group, Montreal, QC, Canada; 4 Ingenix, New Haven, CT, USA OBJECTIVE: This study provides a profile over time of the incremental health care costs of patients treated for depressive disorders, including attention to medical treatment costs, drug treatment costs, and incremental treatment costs (i.e., excess costs as compared to controls) for coexistent medical and psychiatric conditions. METHODS: Administrative claims data from seven large U.S. companies were used to identify 3464 depressive disorder patients. A random sample of individuals who were not treated for depressive disorders served as controls. Incremental cost estimates were generated using a Tobit regression model including controls for age, gender, health plan, geographic location, and a number of medical conditions that tend to precede the onset of depressive disorders. RESULTS: We estimate that treated depressive disorder sufferers incur approximately $608 per month in incremental health care costs during their first depressive disorder episode. Of this total, 29.4 percent are due to medical treatment costs, 6.2 percent are due to drug treatment costs, and 64.4 percent are due to the incremental treatment costs of coexisting conditions. The costs of treating subsequent depressive disorder episodes decline. In addition, while the incremental costs of treating other medical and psychiatric conditions increase in the months prior to the first depression episode, these costs decrease in the months after a final depression episode. CONCLUSION: The health care costs incurred by treated depressive disorder sufferers in the U.S. are substantial. Depressive disorder patients experience a "run up" of costs prior to an episode diagnosis and a subsequent "run down" in costs after treatment for the condition. Future research will investigate the indirect costs (i.e., work loss and work cutback) associated with depressive disorders, as well as the family burden of depressive episodes using the same time profile approach developed here.
